Table 1.
Patient demographics and baseline clinical characteristics (ITT population).
| Atezolizumab + bevacizumab | ||
|---|---|---|
| N = 43 | ||
| Age (years) | Median (range) | 61.0 (33–73) |
| Sex, n (%) | Female | 22 (51.2) |
| Male | 21 (48.8) | |
| Ethnicity, n (%) | Asian | 43 (100) |
| ECOG PS at baseline, n (%) | 0 | 32 (74.4) |
| 1 | 11 (25.6) | |
| LDH at baseline, n (%) | ≤ULN | 33 (76.7) |
| >ULN | 10 (23.3) | |
| BSLD (mm) | Median (range) | 36.3 (10.0–217.0) |
| Advanced stage classification, n (%) | Unresectable disease | 20 (46.5) |
| Metastatic disease | 23 (53.5) | |
| Number of metastatic organ sites, n (%) | n a | 23 |
| <3 | 20 (87.0) | |
| ≥3 | 3 (13.0) | |
| Metastatic site | n a | 23 |
| Lung | 13 (56.5) | |
| Lymph node | 10 (43.5) | |
| Liver | 5 (21.7) | |
| Bone | 2 (8.7) | |
| Other | 2 (8.7) | |
| Adrenal gland | 1 (4.3) | |
| BRAF | Wild-type | 42 (97.7) |
| Mutant | 1 (2.3) | |
| NRAS | Wild-type | 37 (86.0) |
| Mutant | 6 (14.0) | |
| KIT | Wild-type | 36 (83.7) |
| Mutant | 6 (14.0) | |
| NA | 1 (2.3) | |
| Primary disease site | Urogenital | 11 (25.6) |
| Head-neck | 15 (34.9) | |
| Gastrointestinal | 17 (39.5) | |
| Disease stage | Stage III | 19 (44.2) |
| Stage IV | 24 (55.8) |
Abbreviations: BSLD, baseline sum of longest diameter; ULN, upper limit of normal.
aPercentages are based on the population with metastatic mucosal melanoma.